Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Faron Pharmaceuticals Oy ( (GB:FARN) ) has provided an announcement.
Faron Pharmaceuticals has disclosed that its Chief Financial Officer, Jurriaan Dekkers, sold his entire personal holding of 4,000 ordinary shares in the company at a price of £1.822 per share on 12 January 2026, leaving him with no remaining shares and no voting rights. The transaction, reported under market abuse regulation requirements, provides investors with updated information on insider dealings but does not in itself signal any change to Faron’s clinical strategy or operations, which remain centered on advancing its immunotherapy pipeline, including lead candidate bexmarilimab for blood cancers.
More about Faron Pharmaceuticals Oy
Faron Pharmaceuticals Ltd is a global, clinical-stage biopharmaceutical company focused on developing novel immunotherapies to tackle cancer. Its lead asset, bexmarilimab, is an anti-Clever-1 humanized antibody designed to reprogram myeloid cell function and relieve cancer-related immunosuppression, and is currently being evaluated in Phase I/II trials for hematological cancers in combination with standard treatments.
See more data about FARN stock on TipRanks’ Stock Analysis page.